Literature DB >> 25336002

Case of early childhood-onset narcolepsy with cataplexy: comparison with a monozygotic co-twin.

Hiromichi Ito1, Kenji Mori, Tatsuo Mori, Aya Goji, Shoji Kagami.   

Abstract

We describe here a rare case of early childhood-onset (5 years of age) narcolepsy. This case was interesting because of the ability to compare the patient's symptoms to the condition of her healthy monozygotic co-twin sister. The only environmental difference between the co-twins was head injury, which may be associated with the presence of narcolepsy. The co-twin was extroverted, sociable, reliable, and dexterous. In contrast, the patient could be described as introverted, gentle, honest and persevering, but was weak at conversation, assessment of a situation, memory, planning, activity (she was inactive), a sense of time, understanding of an analog clock, operating efficiency, and physical education (due to obesity). The sisters showed the same degree of appetite and dexterity with their fingers. Narcolepsy is often under-recognized or underdiagnosed, especially when the onset occurs in childhood. When we observe preschoolers with excessive daytime sleepiness, we should consider the possibility of narcolepsy with cataplexy.
© 2014 Japan Pediatric Society.

Entities:  

Keywords:  dyssomnia; excessive daytime sleepiness; narcolepsy with cataplexy; orexin; twin

Mesh:

Year:  2014        PMID: 25336002     DOI: 10.1111/ped.12377

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  2 in total

1.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

Review 2.  Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents.

Authors:  Beris Ludwig; Simon Smith; Helen Heussler
Journal:  J Clin Sleep Med       Date:  2018-04-15       Impact factor: 4.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.